Skip to content

Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our privacy policy.

About Motilent

We don’t know enough about how the digestive system really works.

The gastrointestinal tract spans around 9 meters and is responsible for absorbing nutrients from our food. Beyond this it is home to trillions of microbes and thousands of strains of bacteria all contributing to our metabolic and immune health. Coordinating the gastrointestinal tract is the enteric nervous system and brain-gut axis that gives rise to our visceral sensations and allow us to feel our emotions. With all this complexity, it comes as little surprise that things can often go wrong.

With around 20% of the population currently suffering from some form of gastrointestinal disorder, gastrointestinal tract poses an ever-growing challenge in diagnosis and treatment.

Motilent’s mission is to change the way we see the gut. We have spent the last 5 years developing new imaging technology that is helping researchers and clinicians understand how the digestive tract works. Our key clinical focus area is Crohn’s Disease, a debilitating inflammatory condition affecting people of all ages and GIQuant helps clinicians to identify earlier when patients stop responding to immunotherapy.

Innovation at Motilent never stops. Get in touch with us today to find out how we will help you see the future of gastrointestinal physiology with medical imaging.

Our operational team

  • Dr Alex Menys

    Dr Alex Menys

    Founder and Chief Executive Officer

  • Dr Alex Menys

    Dr Alex Menys

    Founder and Chief Executive Officer

    Previous Next
    Alex founded Motilent in 2013 to expedite collaborative research in his field of medical image analysis for gastrointestinal (GI) disorders. Since then, Motilent has grown to working across a range of GI specialties in research and has produced it's first clinically available product for Crohn's disease monitoring - GIQuant. Alex holds master degrees in Biochemistry and Medical Physics, a PhD in MRI imaging and spent 2 years on the board of an AIM listed UK medical device company.
  • Dr Russell Pearson

    Dr Russell Pearson

    Chief Operating Officer

  • Dr Russell Pearson

    Dr Russell Pearson

    Chief Operating Officer

    Previous Next
    Russell joined Motilent in September 2017 to establish it as a medical device manufacturer to bring GIQuant to the market as a CE marked product. Russell holds an MEng in Biomaterials Engineering, a PhD in Bionanotechnology and 5 years experience of medical device regulations, quality systems and project management.
  • Dr Miklos Espak

    Dr Miklos Espak

    Technical Lead

  • Dr Miklos Espak

    Dr Miklos Espak

    Technical Lead

    Previous Next
    Mikos joined Motilent in September 2017 to develop GIQuant into a robust clinical tool, compatible with hospital imaging systems. Miki holds a PhD in computer science and has over 10 years experience in medical imaging and software engineering.
  • Mr Ian Knott

    Mr Ian Knott

    Quality and Regulatory Lead

  • Mr Ian Knott

    Mr Ian Knott

    Quality and Regulatory Lead

    Previous Next
    Ian joined Motilent in October 2018 to focus on the US regulatory market and additional products in Motilent’s portfolio. Ian has over 5 years experience of medical device regulations working both for the MHRA and in the private sector.

Dynamic ‘cine’ MRI offers a new and potentially powerful perspective on gastrointestinal function, especially in conditions like Crohn’s where hypo-motility is related to disease activity. Objective assessment of this data with GIQuant could represent an important advance in how we quantify this in the clinic

Stuart A Taylor, Consultant Radiologist and Professor of Medical Imaging, UCL